Naab Al‐Saady - Concepedia

Author

Naab Al‐Saady

Also Known As

NAAB AL-SAADY, NAAB Al‐SAADY, Naab Al-Saady, Naab Al‐Saady, Naab M Al-Saady, Naab M. Al-SAADY, Naab M. Al-Saady, Naab M. Al‐Saady

Publications

948

Citations

H-Index

Concepts

All Affiliations

St George's Hospital St George's, University of London Covance (United Kingdom)University Hospital Magdeburg Daiichi Sankyo (United States)

About

Naab Al‐Saady is an author at St George's Hospital specializing in cardiovascular disease, medicine, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	633
2	Public Health	5	5	534
3	Pharmacology	5	5	461
4	Diabetes	1	1	99
5	Endocrinology	1	1	59

Naab Al‐Saady

Publications

917

Citations

H-Index

Page 1

	Year	Citations
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial Andreas Goette, José Luís Merino, Michael D. Ezekowitz, The Lancet ThrombosisCardiovascular DiseasePharmacologyCardiovascular PharmacologyPharmacotherapy	2016	243
Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion Mark M. Gallagher, Brian J. Hennessy, Nils Edvardsson, Journal of the American College of Cardiology Cardiogenic ShockCardiac AnaesthesiaEmbolic ComplicationsCardiovascular DiseaseAtrial Arrhythmias	2002	172
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study John J.P. Kastelein, Joost Besseling, Sukrut Shah, The Lancet Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaCardiovascular DiseaseDiabetes	2015	99
Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa B. Alexander Yi, Debra Freedholm, Nancy Widener, Journal of Thrombosis and Haemostasis	2021	92
Advantages of a narrow-range, medium molecular weight hydroxyethyl starch for volume maintenance in a porcine model of fecal peritonitis Andrew Webb, D. Tighe, RAY F. MOSS, Critical Care Medicine	1991	64
Goal-directed therapy with dopexamine, dobutamine, and volume expansion D. Tighe, R. Moss, G Heywood, Critical Care Medicine	1995	61
5-hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle? Shamil Yusuf, Naab Al‐Saady, A. John Camm PubMed Cardiovascular ToxicityHeart FailureCardiac AnaesthesiaPotential BenefitsCardiovascular Disease	2003	59
Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model DEREK TIGHE RAY MOSS, JOHN HYND SEDA BOGHOSSIAN, Naab Al‐Saady, Critical Care Medicine	1990	56
5‐Hydroxytryptamine and Atrial Fibrillation: Shamil Yusuf, Naab Al‐Saady, A. John Camm Journal of Cardiovascular Electrophysiology Molecular PharmacologyCardiac AnaesthesiaPotential BenefitsCardiovascular DiseaseMedicine	2003	44
Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin – Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial) Gregory Y.H. Lip, Naab Al‐Saady, James Jin, The American Journal of Cardiology ThrombosisCardiovascular DiseasePharmacologyCardiovascular PharmacologyAtrial Fibrillation Trial	2017	16

Page 1